Exchange: NASDAQ·Updated 07:30 PM EST
KNSA logo

KNSA Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

$94.23
$2.10
(2.18%)
Today
Closed $94.23
$0.00
(0.00%)
After Hours
Reported EarningsOct 27
Mkt Cap$7.57B
Vol455,883.00

About KNSA

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
41

Bearish Sentiment

How do you feel about KNSA?

Paperstocks89
$KNSA typical taps a 52 wk high and is sold down to 79. If this is as strong as it looks over last few weeks it was a last opportunity to get a decent price sub 80 of a breakout is real
1
shoc24
$KNSA is ranked #25 in healthcare momentum with a score of 83. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
shoc24
$KNSA Reported today: EPS of $0.56 vs. $0.37 expected (+50.9%, beat). Revenue of $286M vs. $261M expected (+9.7%, beat). I used Stock Meadow’s earnings dashboard to review the results.
RTPRwire
$KNSA is active on earnings beat following a Globe Newswire release. Kiniksa reports Q3 2026 ARCALYST revenue of $286M with 58% YoY growth, raising full-year guidance to $1.045-$1.050B. RTPR pushed this release out to users at 7:30:03 AM ET
BiotechSwings
Earnings morning and $KNSA is the one actually moving Q3 earnings 56 cents, up from 23 cents a year ago, on 286 million in revenue vs 181 million last year ARCALYST sales up about 58% and management lifted full year guidance to about 1.05 billion that is a commercial engine actually working, not a promise on a pipeline slide
Merlintrader
$KNSA — Q3: revenue $286.0M, net income $47.3M, cash $568.8M. 2026 guidance raised to $1.045–1.050B (third raise this year). PASTORALE data expected in 2H 2027. Information only — not investment advice. More details in our hub.
filecrux
$KNSA Is Kiniksa's raised $1,045M–$1,050M 2026 ARCALYST sales forecast conservative after a $286.0M third quarter? 🚀 Kiniksa, a drugmaker whose ARCALYST is a weekly injection for recurrent pericarditis and whose market value was about $5.58B at $72.98 a share at 16:00 ET on October 26, 2026, raised its 2026 ARCALYST net product revenue forecast to $1,045M–$1,050M from $980M–$995M after third-quarter sales of $286.0M rose about 58% from a year earlier ⚠️ Collaboration expenses, which the company says are driven primarily by ARCALYST collaboration profitability, rose to $105.8M from $63.3M and took about 37% of third-quarter revenue, so holders keep only part of each extra sales dollar 📅 Next: KPL-1161 Phase 1 trial to start by the end of 2026 Source: GlobeNewswire release + SEC 8-K, Oct 27
TrianglePlay2
$KNSA Firm Price target Before earning... upgrade coming JPMorgan $107 Citigroup $100 Wedbush $99 Canaccord Genuity $98 TD Cowen $95 Goldman Sachs $90 Wells Fargo $87
StocktwitsEarnings
$KNSA Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.56 up 143.48% YoY • Reported revenue of $285.97M up 58.13% YoY • Kiniksa expects 2026 ARCALYST net product revenue between $1.05B and $1.05B, 2026 R&D expenses of $160M to $170M, and SG&A expenses of $270M to $280M.
TrianglePlay2
$KNSA Other encouraging developments Net income: $47.3 million, compared with $18.4 million a year ago. Patient adoption: Approximately 23% of the estimated 14,000 multiple-recurrence patients were receiving ARCALYST, up from 21% last quarter. Cash position: $568.8 million, with no debt. Drug pipeline: KPL-387 Phase 3 results are expected in the second half of 2027.
TrianglePlay2
$KNSA Metric Wall Street estimate Actual Result Revenue $260.7M $286.0M Beat +9.7% Diluted EPS $0.37 $0.56 Beat +51.4% ARCALYST sales growth YoY — +58% Strong growth
Rayvio_News_Filter
$KNSA 🏥 Idorsia Pharmaceuticals Ltd will pursue a new development program for daridorexant 50 mg in autism spectrum disorder following unexpected improvements in affect and behavior in a Phase 2 pediatric insomnia study.
Rayvio_News_Filter
$KNSA 🏥 Idorsia presents positive clinical results for daridorexant in children and adolescents with insomnia, with a single 50 mg dose increasing sleep time by 50 minutes overall and 64 minutes in children with neurodevelopmental disorders. Market-relevant event

Advertisement|Remove ads.